Eris Lifesciences Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks
- May 8, 2026
- Posted by: Neeraj Pandey
- Category: News
The Eris Lifesciences share price target for 2026 stands at Rs 1185 as per the latest analyst forecast, implying 26 percent upside from the current market price of Rs 940. Investors tracking the Eris Lifesciences share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the Eris Lifesciences share price target thesis updated April 2026.
Click Here to Get Free Investment Predictions on Univest
Track live Eris Lifesciences price, FII or DII flows and analyst targets on the Univest Screener.
Eris Lifesciences Company Overview
Tap to Access Best Research on Univest
Eris Lifesciences (NSE: ERIS) is a listed company in India’s Pharma sector with a market capitalisation of Rs 12879 crore. At CMP Rs 940 against a 52 week range of Rs 770 to Rs 1080, the stock currently offers meaningful upside to the analyst price forecast of Rs 1185. For more share price target analysis, visit Univest Blogs.
| Parameter | Value |
|---|---|
| NSE Ticker | ERIS |
| Sector | Pharma |
| CMP April 2026 | Rs 940 |
| 52 Week High | Rs 1080 |
| 52 Week Low | Rs 770 |
| Market Cap | Rs 12879 crore |
| Trailing P/E | 22x |
| 12M Analyst Price Forecast | Rs 1185 |
| Bull Case Target | Rs 1420 |
| Bear Case Target | Rs 712 |
Why Analysts Set the Eris Lifesciences Share Price Target at Rs 1185 for 2026
FY27 Earnings Delivery and Revenue Acceleration
FY27 is the key year where analysts expect Eris Lifesciences to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 940 and the Eris Lifesciences share price target 2026 of Rs 1185. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.
Digital transformation driving efficiency gains
Digital transformation driving efficiency gains is a key growth driver that analysts highlight in supporting the Eris Lifesciences share price target of Rs 1185. The Pharma sector is expanding at 12 to 18 percent annually, and Eris Lifesciences is well-positioned to capture a rising share. Discover top Pharma stocks on the Univest Screener.
Debt reduction improving return ratios
Debt reduction improving return ratios provides an additional lever that can help Eris Lifesciences exceed analyst projections and potentially push the stock toward the bull case target of Rs 1420. Compare Eris Lifesciences with sector peers on the Univest Screener.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s rate cut cycle that commenced in 2026 reduces Eris Lifesciences’s borrowing costs and stimulates end-market demand, supporting the Eris Lifesciences share price target 2026 of Rs 1185.
Union Budget 2026-27 Policy Support
Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for Eris Lifesciences’s Pharma business, directly supporting the Eris Lifesciences share price target 2026 bull case of Rs 1420.
Bull Case, Base Case and Bear Case for Eris Lifesciences Share Price Target
| Scenario | Target | Key Assumption |
|---|---|---|
| Bull Case | Rs 1420 | FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating |
| Base Case Forecast | Rs 1185 | FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained |
| Bear Case | Rs 712 | Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating |
For live tracking of Eris Lifesciences analyst price targets and ratings, use the Univest Screener.
Key Risks to the Eris Lifesciences Share Price Target
Earnings Miss Risk
If Eris Lifesciences reports quarterly earnings below expectations, the Eris Lifesciences share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.
Macro and Global Headwinds
The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the Eris Lifesciences share price target 2026 timeline.
Sector-Specific Risks
Regulatory changes, input cost volatility, and competitive intensity in the Pharma space could pressure margins and delay realisation of the Eris Lifesciences share price target of Rs 1185.
FII Outflows
Continued FII selling in Indian equities could suppress the valuation multiples needed for Eris Lifesciences to reach its analyst price forecast of Rs 1185 within the 12 month horizon.
Eris Lifesciences Financial Snapshot FY25 to FY27
| Metric | FY25 Actual | FY26 Estimate | FY27 Estimate |
|---|---|---|---|
| Revenue (Rs Cr) | Refer NSE filing | Refer NSE filing | Refer NSE/BSE filing |
| EBITDA Margin | Refer NSE filing | Refer NSE filing | Expected expansion |
| PAT (Rs Cr) | Refer NSE filing | Refer NSE filing | 15 to 20 percent growth |
| Market Cap | Rs 12879 crore | Higher at 52W peak | Tracks price movement |
| P/E Ratio | 22x | Current level | Target implies re-rating |
| 52 Week High / Low | Rs 1080 / Rs 770 | ||
If you want to track Eris Lifesciences financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.
Technical Outlook for Eris Lifesciences Share Price
Eris Lifesciences is trading at Rs 940, currently attempting to build a base above its 52 week low of Rs 770. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The Eris Lifesciences share price target of Rs 1185 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track Eris Lifesciences live price and set alerts.
Conclusion
The Eris Lifesciences share price target 2026 of Rs 1185 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 1420 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.
This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.
Frequently Asked Questions
What is the Eris Lifesciences share price target for 2026?
The Eris Lifesciences share price target for 2026 is Rs 1185 as per the analyst price forecast, implying 26 percent upside from the current price of Rs 940. The bull case target is Rs 1420 and the bear case is Rs 712.
Is Eris Lifesciences a good buy at Rs 940?
At Rs 940, Eris Lifesciences trades at a trailing P/E of 22x and offers potential upside to the analyst price forecast of Rs 1185. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.
What is the 52 week high and low of Eris Lifesciences?
The 52 week high of Eris Lifesciences is Rs 1080 and the 52 week low is Rs 770. The current CMP of Rs 940 positions the stock at a meaningful discount to its peak, which is factored into the analyst Eris Lifesciences share price target 2026.
What sector does Eris Lifesciences belong to?
Eris Lifesciences belongs to India’s Pharma sector and trades on NSE with the ticker ERIS. Track the entire Pharma sector on the Univest Screener.
What is the bull case for Eris Lifesciences share price?
The bull case for Eris Lifesciences share price is Rs 1420, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Pharma sector. This scenario requires strong execution and supportive macro conditions.
What are the key risks to the Eris Lifesciences share price target?
Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Pharma sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 712.
Recent Article
Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026
